AMSTERDAM and DENVER, June 11,
2017 /PRNewswire/ -- Royal Philips (NSYE: PHG,
AEX: PHIA) today announced that it will be showcasing molecular
imaging solutions highlighting Philips' commitment to innovation
and more personalized care at the Society of Nuclear Medicine and
Molecular Imaging (SNMMI) 2017 Annual Meeting. Molecular imaging
provides insight into molecular and cellular processes in the body,
and has the potential to transform healthcare by offering earlier
detection and more precise treatment of diseases. Philips continues
to bring solutions into the field of nuclear medicine that enhance
quantitative accuracy and enable new clinical applications driving
more personalized care and workflow efficiencies from diagnosis to
treatment.
Nuclear medicine technology has significantly evolved over
the years – growing from just scanners to solutions that comprise
systems and advanced informatics, for enhanced image quality,
quantification and analytics. As value-based care changes the way
healthcare organizations approach care delivery, there is a greater
need for easy to use, fast and precise imaging. With increased
access to better data, clinicians are looking for ways to make that
data actionable, especially in terms of customizing patient
treatment. Molecular imaging accomplishes that, allowing physicians
to make decisions based on the specific molecular and cellular
patterns of disease in addition to the patient's
anatomy.
"Molecular imaging today allows physicians to make decisions
with greater insight, precision and confidence, bringing healthcare
one step closer to personalized care," said Kirill Shalyaev, Ph.D.,
Business Leader, Advanced Molecular Imaging,
Philips. "Philips has made a lasting impact in nuclear
medicine by providing clinicians with innovations such as
Time-of-Flight PET and digital PET/CT, and we remain dedicated to
developing solutions that simplify the path to clinical decision
making for more confident diagnosis and a faster path to
treatment."
Even with its significant growth in past years, the opportunity
for further innovation and growth in nuclear medicine remains,
continuing to maximize its value and impact. Philips' SNMMI exhibit
(booth 657) will feature the company's latest solutions and
technologies driving the future of nuclear medicine:
- Vereos Digital PET/CT – The world's first and only fully
digital PET/CT system featuring Philips proprietary Digital Photon
Counting (DPC) technology. Vereos offers improved detectability and
characterization of small lesions[1]. The system provides
uncompromised detectability and quantification at half the
PET dose[2]. Vereos also provides lesion detectability in one
tenth of the time[3].
- Ingenuity TF PET/CT – Leverages Philips'
Astonish TF technology for enhanced image contrast, resolution, and
quality. Features Philips' proprietary xPand5 quantification tools
to assist in measuring and monitoring disease progression. These
technologies join CT advances, such as iPatient, iDose⁴and metal
artifact reduction for implants (O-MAR), to drive confidence and
consistency through personalized patient centric workflow.
- IntelliSpace Portal 9.0 – IntelliSpace Portal 9.0 – The
latest edition of Philips' comprehensive, advanced visualization
and analysis platform offers quantitative tumor tracking and
treatment response tools with a streamlined workflow for follow‐up
and analysis in oncology cases. IntelliSpace Portal 9.0 provides
enterprise‐wide access to a comprehensive suite of Molecular
Imaging processing and review applications for general Nuclear
Medicine, SPECT, SPECT/CT and PET/CT.
- SPECT Solutions – To fulfill the need for
clinically dependable SPECT systems, Philips provides
cost-efficient cardiac and general-purpose SPECT solutions that
maximize the return on investment.
Innovation Talks
This year, Philips will host a number of talks and presentations at
its booth (#657) at SNMMI. In addition, Philips' academic partners
will present 19 scientific presentations and posters demonstrating
the value Philips' digital PET/CT system is bringing to molecular
imaging – advancing knowledge and application using features such
as lesion detection and quantitative imaging.
For more information on Philips' molecular imaging solutions,
and to learn more about the company's presence at SNMMI 2017, visit
booth 657, www.philips.com/snmmi and follow the conversation
on @PhilipsLiveFrom.
For further information, please contact:
Alicia
Cafardi
Philips Group
Communications
Tel: + 1
412-523-9616
E-mail:
alicia.cafardi@philips.com
About Royal
Philips
Royal
Philips (NYSE: PHG, AEX: PHIA) is a leading health
technology company focused on improving people's health and
enabling better outcomes across the health continuum from healthy
living and prevention, to diagnosis, treatment and home care.
Philips leverages advanced technology and deep clinical and
consumer insights to deliver integrated solutions. Headquartered in
the Netherlands, the company is a
leader in diagnostic imaging, image-guided therapy, patient
monitoring and health informatics, as well as in consumer health
and home care. Philips' health technology portfolio generated 2016
sales of EUR 17.4 billion and employs
approximately 70,000 employees with sales and services in more than
100 countries. News about Philips can be found at
www.philips.comnewscenter.
[1] Nguyen NC, Image Quality and Diagnostic
Performance of a Digital PET Prototype in Patients with Oncologic
Diseases: Initial Experience and Comparison with Analog PET, J Nucl
Med 2015; 56:1378–1385.
[2] Liu X et al, Impact of
FDG Dose Reduction on Lesion Quantification in Dynamic PET: A
Simulation Study Based on Clinical Trial Data, SNMMI
2016.
[3] Zhang J., Evaluation of speed of PET
acquisition: How fast can we go? - A validation of list mode PET
simulation approach with true acquisitions, SNMMI 2017.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/philips-highlights-the-value-of-advanced-molecular-imaging-at-snmmi-2017-300472014.html
SOURCE Royal Philips